Characterization of carfilzomib-resistant non-small cell lung cancer cell lines.
AuthorHanke, Neale T
Marron, Marilyn T
Seligmann, Bruce E
Garland, Linda L
Baker, Amanda F
AffiliationUniv Arizona, Ctr Canc, Coll Med, Tucson, AZ 85721 USA
Non-small cell lung cancer
MetadataShow full item record
CitationHanke, N. T., Imler, E., Marron, M. T., Seligmann, B. E., Garland, L. L., & Baker, A. F. (2018). Characterization of carfilzomib-resistant non-small cell lung cancer cell lines. Journal of cancer research and clinical oncology, 144(7), 1317-1327.
Rights© Springer-Verlag GmbH Germany, part of Springer Nature 2018
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at firstname.lastname@example.org.
AbstractWe previously showed that carfilzomib (CFZ) has potent anti-proliferative and cytotoxic activity in a broad range of lung cancer cell lines. Here we investigate possible mechanisms of CFZ acquired resistance in lung cancer cell lines. CFZ-resistant non-small cell lung cancer (NSCLC) cell lines were developed by exposing A549 and H520 cells to stepwise increasing concentrations of CFZ. Resistance to CFZ and cross-resistance to bortezomib and other chemotherapy drugs was measured using the MTT assay. Cytotoxicity to CFZ was determined using a CytoTox assay. Western blot was used to measure apoptosis, autophagy, and drug efflux transporter-related proteins. Quantitative targeted whole transcriptome sequencing and quantitative RT-PCR was used to measure gene expression. Flow cytometry was used to analyze intracellular accumulation of doxorubicin. The CFZ IC Upregulation of Pgp appears to be an important, but not the only, mechanism of CFZ resistance in NSCLC cell lines.
Note12 month embargo; published online 15 May 2018
VersionFinal accepted manuscript
SponsorsOnyx Pharmaceuticals, Inc.; Basic/Clinical Translational Partnership Pilot Grant award from the Arizona Cancer Center Support Grant [P30CA023074]; Basic/Clinical Translational Partnership Pilot Grant award from National Cancer Institute (NCI) [P30CA023074]
- Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.
- Authors: Baker AF, Hanke NT, Sands BJ, Carbajal L, Anderl JL, Garland LL
- Issue date: 2014 Dec 31
- Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines.
- Authors: Hanke NT, Garland LL, Baker AF
- Issue date: 2016 Mar
- The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
- Authors: Gu JJ, Hernandez-Ilizaliturri FJ, Kaufman GP, Czuczman NM, Mavis C, Skitzki JJ, Czuczman MS
- Issue date: 2013 Sep
- Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
- Authors: Li JH, Luo N, Zhong MZ, Xiao ZQ, Wang JX, Yao XY, Peng Y, Cao J
- Issue date: 2016 Feb
- EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
- Authors: Gao J, Meng Q, Zhao Y, Chen X, Cai L
- Issue date: 2016 Jul 13